Noze is pioneering a transformative approach to healthcare through its innovative digital odor perception platform, which is designed to detect diseases by analyzing the volatile organic compounds (VOCs) present in human breath. This technology, inspired by the natural capabilities of the human nose, utilizes a specialized sensor to collect breath samples, creating unique "digital scentprints" that are then analyzed by a sophisticated AI engine. This engine is capable of identifying disease biomarkers in real-time, allowing for immediate diagnostics without the need for laboratory testing. The platform aims to facilitate early disease detection across various medical conditions, including diabetes, tuberculosis, and certain cancers, thereby enhancing patient outcomes and promoting preventive healthcare.

The flagship product under development, DiagNoze®, represents the world's first fully-integrated diagnostic breathalyzer, which will enable healthcare providers to conduct routine screenings and diagnose diseases from any point-of-care setting. With a focus on accessibility and cost-effectiveness, DiagNoze® is set to revolutionize medical diagnostics by providing non-invasive testing solutions that can be integrated into medical devices and consumer wearables. Additionally, Noze's technology has applications beyond healthcare, including monitoring indoor air quality and detecting food spoilage, showcasing its versatility and potential impact across multiple sectors.

Canada

Noze is the global leader in digital odor perception (often hailed as the digital equivalent of the sense of smell). We have developed the world's most advanced digital nose, capable of detecting and identifying odors in real-world settings with unparalleled accuracy. Leveraging cutting-edge machine intelligence and a sensor developed with exclusively licensed NASA technology, Noze is committed to enhancing human health and wellbeing. Our mission is to improve patient outcomes by enabling real-time disease detection at any point-of-care by using our technology to target breath-based odor biomarkers.

Noze

Company Details